Featured Research

from universities, journals, and other organizations

Fast-tracked Medications More Likely To Face Later Regulatory Action To Remedy Safety Concerns

Date:
March 27, 2008
Source:
Harvard University
Summary:
According to new research many drugs are approved on the brink of FDA deadlines, and these drugs are more likely to later face regulatory intervention for safety reasons. Drugs fast-tracked by the FDA are more likely to eventually be withdrawn from global markets for safety reasons, undergo manufacturing revisions, or face labeling changes.

Many medications are approved by the U.S. Food and Drug Administration on the brink of congressionally mandated deadlines, and those drugs are more likely to face later regulatory intervention than those approved with greater deliberation, researchers at Harvard University have found. Drugs fast-tracked by the FDA are more likely to eventually be withdrawn from global markets for safety reasons, undergo manufacturing revisions, or face labeling changes, according to Daniel Carpenter, professor of government in Harvard's Faculty of Arts and Sciences.

"We found that while these deadlines speed up the approval process, many drugs are approved right up against the deadline, which might lead to unintended consequences with regard to drug safety," says Carpenter. "This suggests that drug safety might improve under an FDA approval protocol that is more flexible and less driven by deadline pressures and more by stable growth in FDA resources."

The deadlines imposed on the FDA's drug-approval process were first enacted as part of the Prescription Drug User Fee Act (PDUFA) of 1992, which mandated that the FDA must act on 90 percent of all drug candidates within 12 months of submission or face funding cuts. The timeline was tightened to 10 months as part of the 1997 Food and Drug Administration Modernization Act, a timeline extended by Congress in 2002 as part of bioterrorism legislation and renewed again in 2007.

Some observers have suggested that these deadlines lead to the rushed approval of medications, a theory Carpenter tested by examining data on the timing of FDA approvals dating back to 1950. He found that the enactment of PDUFA in 1992 appeared to introduce a temporal discontinuity into FDA review cycles, with disproportionate approvals coming in the two months immediately before deadlines. Compared to drugs approved at a more measured pace in the months following the deadline, those approved right before the review clock expired were far more likely to require later regulatory intervention.

"Drugs rushed to approval just before the deadline are two to three times more likely to eventually be pulled off shelves due to safety concerns, two to seven times more likely to receive added label warnings known as 'black box revisions,' twice as likely to experience changes in manufacture, and two to seven times more likely to be voluntarily discontinued by manufacturers due to weak clinical demand," says Carpenter.

In previous work, Carpenter developed a mathematical model to understand how government agencies "learn" and how deadlines affect organizational behavior. This model predicts the pattern of outcomes described in the New England Journal study.

Fifty years ago, the FDA approved most new medications within a few months of receiving applications from manufacturers. Over time, the process slowed as new review protocols were added in the wake of pharmaceutical missteps such as thalidomide, which led to the births of thousands of deformed babies in the late 1950s and early 1960s.

"Because of similarly high-profile regulatory mistakes in recent years, we will likely see greater congressional scrutiny in coming decades as these FDA deadlines come up for renewal every five years," Carpenter says. "While we are not arguing that these deadlines should be abandoned, our research indicates that mechanisms other than strict deadlines may better balance the need for expeditious yet rigorous drug approval."

The research will be published in the Mar. 27 issue of the New England Journal of Medicine. Carpenter's co-authors were Jerry Avorn, Professor of Medicine at Harvard Medical School/chief, Division of Pharmacoepidemiology at Brigham and Women's Hospital and Evan James Zucker, a student at Harvard Medical School.

The research was funded by the Robert Wood Johnson Foundation, the National Science Foundation, and Harvard's Center for American Political Studies and Institute for Quantitative Social Science.


Story Source:

The above story is based on materials provided by Harvard University. Note: Materials may be edited for content and length.


Cite This Page:

Harvard University. "Fast-tracked Medications More Likely To Face Later Regulatory Action To Remedy Safety Concerns." ScienceDaily. ScienceDaily, 27 March 2008. <www.sciencedaily.com/releases/2008/03/080326172057.htm>.
Harvard University. (2008, March 27). Fast-tracked Medications More Likely To Face Later Regulatory Action To Remedy Safety Concerns. ScienceDaily. Retrieved August 30, 2014 from www.sciencedaily.com/releases/2008/03/080326172057.htm
Harvard University. "Fast-tracked Medications More Likely To Face Later Regulatory Action To Remedy Safety Concerns." ScienceDaily. www.sciencedaily.com/releases/2008/03/080326172057.htm (accessed August 30, 2014).

Share This




More Health & Medicine News

Saturday, August 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

3 Things To Know About The Ebola Outbreak's Progression

3 Things To Know About The Ebola Outbreak's Progression

Newsy (Aug. 29, 2014) Here are three things you need to know about the deadly Ebola outbreak's progression this week. Video provided by Newsy
Powered by NewsLook.com
Killer Amoeba Found in Louisiana Water System

Killer Amoeba Found in Louisiana Water System

AP (Aug. 28, 2014) State health officials say testing has confirmed the presence of a killer amoeba in a water system serving three St. John the Baptist Parish towns. (Aug. 28) Video provided by AP
Powered by NewsLook.com
Who Could Be Burnt by WHO's E-Cigs Move?

Who Could Be Burnt by WHO's E-Cigs Move?

Reuters - Business Video Online (Aug. 28, 2014) The World Health Organisation has called for the regulation of electronic cigarettes as both tobacco and medical products. Ciara Lee looks at the impact of the move on the tobacco industry. Video provided by Reuters
Powered by NewsLook.com
CDC Director On Ebola Outbreak: 'It's Worse Than I Feared'

CDC Director On Ebola Outbreak: 'It's Worse Than I Feared'

Newsy (Aug. 28, 2014) CDC director Tom Frieden says the Ebola outbreak is even worse than he feared. But he also said there's still hope to contain it. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins